Alembic Pharma slumps after receiving two USFDA observations for karakhadi facility

Alembic Pharmaceuticals fell 1.26% to Rs 766.50 after the US Food and Drug Administration (USFDA) completed a current Good Manufacturing Practices inspection of the company's Karakhadi facility in Vadodara, Gujarat.

The inspection was conducted from 9th February to 18th February 2026. At the end of the inspection, a Form 483 was issued with 2 observations and the company said that it will respond to the US FDA within the stipulated timelines.

Alembic Pharmaceuticals, a vertically integrated research and development company, is engaged in the manufacture and marketing of generic pharmaceutical products across global markets.

The companys consolidated net profit fell 3.9% to Rs 132.97 crore despite a 10.8% jump in net sales to Rs 1,876.31 crore in Q3 FY26 over Q3 FY25.

Powered by Capital Market - Live News